Small font size A Larger text size A Largest text size A

KalVista Pharmaceuticals Proposes Private Offering of $110 Million of Convertible Notes; Shares Fall After Hours

BY MT Newswires | CORPORATE | 09/24/25 04:20 PM EDT

04:20 PM EDT, 09/24/2025 (MT Newswires) -- KalVista Pharmaceuticals (KALV) said late Wednesday it plans to issue $110 million of convertible senior notes due 2031 in a private placement, subject to market conditions.

KalVista plans to give initial purchasers an option to buy up to an additional $15 million of notes.

Net proceeds from the planned offering will be for working capital and other general corporate purposes, the company said, adding it may also use part of the proceeds for investments in and acquisitions of other companies, products or technologies.

The company's shares were down 9.1% in after-hours activity.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

More Fixed Income News

CANADA STOCKS-TSX futures dip ahead of BoC, Fed interest rate decisions BY Reuters |ECONOMIC 06:30 AM EST
PRECIOUS-Gold dips ahead of Fed decision; silver extends rally above $60 BY Reuters |ECONOMIC 06:30 AM EST
Wall St futures slip ahead of Fed meeting, 2026 cuts in doubt BY Reuters |ECONOMIC 06:30 AM EST
US STOCKS-Wall St futures slip ahead of Fed meeting, 2026 cuts in doubt BY Reuters |ECONOMIC 06:24 AM EST

All Fixed Income News

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article